scholarly journals Allogeneic stem cell transplantation in treatment of chronic myeloid leukaemia – current approach in tyrosine kinase inhibitors era

2010 ◽  
Vol 1 ◽  
pp. 31-38
Author(s):  
Lidia Gil ◽  
Krzysztof Lewandowski ◽  
Mieczysław Komarnicki
Keyword(s):  
Stem Cell ◽  
Chronic Myeloid Leukaemia ◽  
Stem Cell Transplantation ◽  
Tyrosine Kinase ◽  
Myeloid Leukaemia ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Kinase Inhibitors ◽  
Current Approach

The Treatment of Chronic Myeloid Leukaemia (CML) in the Era of Tyrosine Kinase Inhibitors – What is New in the Battle of CML?

2015 ◽  
Vol 11 (1) ◽  
pp. 30 ◽  
Author(s):  
Dilek Keskin ◽  
Ahmet Emre Eskazan ◽  
◽  
Keyword(s):  
Stem Cell ◽  
Chronic Myeloid Leukaemia ◽  
Stem Cell Transplantation ◽  
Tyrosine Kinase ◽  
Myeloid Leukaemia ◽  
Tyrosine Kinase Inhibitors ◽  
Haematopoietic Stem Cell Transplantation ◽  
Therapeutic Strategy ◽  
Kinase Inhibitors ◽  
Haematopoietic Stem Cell

As the development of BCR-ABL1 targeting treatments has proceeded – first imatinib, then nilotinib and dasatinib – the treatment of chronic myeloid leukaemia (CML) has been revolutionised, and most patients live longer. Since tyrosine kinase inhibitors (TKIs) are expensive, generic imatinibs were introduced in order to overcome this matter. Allogeneic haematopoietic stem cell transplantation is still a treatment option in selected cases. Recent advances in targeting the CML stem cell suggested that this approach alone or together with TKIs could be an alternative therapeutic strategy for curing this disease.

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

Blood ◽  
2011 ◽  
Vol 117 (3) ◽  
pp. 755-763 ◽  
Author(s):  
Jiří Pavlů ◽  
Richard M. Szydlo ◽  
John M. Goldman ◽  
Jane F. Apperley
Keyword(s):  
Stem Cell ◽  
Chronic Myeloid Leukemia ◽  
Stem Cell Transplantation ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Transplantation ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Chronic Phase ◽  
Hematopoietic Stem

Abstract Last year marked 30 years of hematopoietic stem cell transplantation as a curative treatment of chronic myeloid leukemia (CML). Initially studies used stem cells from identical twins but techniques rapidly developed to use cells first from HLA-identical siblings and later unrelated donors. During the 1990s CML became the most frequent indication for allogeneic transplantation worldwide. This, together with the relative biologic homogeneity of CML in chronic phase, its responsiveness to graft-versus-leukemia effect and the ability to monitor low level residual disease placed CML at the forefront of research into different strategies of stem cell transplantation. The introduction of BCR-ABL1 tyrosine kinase inhibitors during the last decade resulted in long-term disease control in the majority of patients with CML. In those who fail to respond and/or develop intolerance to these agents, transplantation remains an effective therapeutic solution. The combination of tyrosine kinase inhibitors with transplantation is an exciting new strategy and it provides inspiration for similar approaches in other malignancies.

Sign in / Sign up

Export Citation Format

Share Document